CL2012000640A1 - Uso del compuesto n-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamina o su sal para el tratamiento de cancer refractario a tratamiento con un agente anti-cancer. - Google Patents

Uso del compuesto n-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamina o su sal para el tratamiento de cancer refractario a tratamiento con un agente anti-cancer.

Info

Publication number
CL2012000640A1
CL2012000640A1 CL2012000640A CL2012000640A CL2012000640A1 CL 2012000640 A1 CL2012000640 A1 CL 2012000640A1 CL 2012000640 A CL2012000640 A CL 2012000640A CL 2012000640 A CL2012000640 A CL 2012000640A CL 2012000640 A1 CL2012000640 A1 CL 2012000640A1
Authority
CL
Chile
Prior art keywords
treatment
cancer
phthalazinamine
pyridinyl
pyrimidinyl
Prior art date
Application number
CL2012000640A
Other languages
English (en)
Inventor
Marc Kendall Richard Payton
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43216900&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012000640(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2012000640A1 publication Critical patent/CL2012000640A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Abstract

Uso del compuesto n-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamina o su sal para el tratamiento de cáncer refractario a tratamiento con un agente anti-cáncer.
CL2012000640A 2009-09-11 2012-03-12 Uso del compuesto n-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamina o su sal para el tratamiento de cancer refractario a tratamiento con un agente anti-cancer. CL2012000640A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24152709P 2009-09-11 2009-09-11

Publications (1)

Publication Number Publication Date
CL2012000640A1 true CL2012000640A1 (es) 2012-09-21

Family

ID=43216900

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000640A CL2012000640A1 (es) 2009-09-11 2012-03-12 Uso del compuesto n-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamina o su sal para el tratamiento de cancer refractario a tratamiento con un agente anti-cancer.

Country Status (33)

Country Link
US (1) US20120028917A1 (es)
EP (2) EP2818170B1 (es)
JP (1) JP5851403B2 (es)
KR (1) KR20120082896A (es)
CN (1) CN102869361A (es)
AU (1) AU2010292225C1 (es)
BR (1) BR112012008325A2 (es)
CA (1) CA2773838C (es)
CL (1) CL2012000640A1 (es)
CR (1) CR20120171A (es)
DK (1) DK2475368T3 (es)
EA (1) EA020526B1 (es)
ES (1) ES2528485T3 (es)
HK (2) HK1173655A1 (es)
HR (1) HRP20150104T1 (es)
HU (1) HUE024568T2 (es)
IL (1) IL218569A0 (es)
MA (1) MA33658B1 (es)
ME (1) ME02048B (es)
MX (1) MX2012003041A (es)
NZ (1) NZ598758A (es)
PE (1) PE20120895A1 (es)
PL (1) PL2475368T3 (es)
PT (1) PT2475368E (es)
RS (1) RS53807B1 (es)
SG (1) SG179102A1 (es)
SI (1) SI2475368T1 (es)
SM (1) SMT201500028B (es)
TN (1) TN2012000110A1 (es)
TW (1) TW201121956A (es)
UA (1) UA107675C2 (es)
WO (1) WO2011031842A1 (es)
ZA (1) ZA201202472B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8921367B2 (en) 2012-05-31 2014-12-30 Amgen Inc. Use of AMG 900 for the treatment of cancer
CN103664737A (zh) * 2012-09-25 2014-03-26 杨子娇 一类治疗房角狭窄的化合物及其用途
US9963701B2 (en) 2013-09-30 2018-05-08 Korea Institute Of Radiological & Medical Sciences Pharmaceutical composition for treatment of radiation- or drug-resistant cancer comprising HRP-3 inhibitor
DK3068393T5 (da) 2013-11-11 2022-08-22 Amgen Inc Kombinationsterapi som inkluderer en mdm2-inhibitor og et eller flere yderligere farmaceutisk aktive midler til behandlingen af kræftformer
AU2014357545B2 (en) * 2013-12-03 2018-10-25 Amgen Inc. Crystalline forms of N-(4-((3-(2-amino-4-pyrimidinyl) - 2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1 -phthalazinamine pharmaceutically acceptable salts and uses thereof
CN114634483A (zh) * 2014-02-21 2022-06-17 弗洛斯特生物科技有限公司 用于治疗癌症和增殖性疾病的抗有丝分裂酰胺
AU2017248807A1 (en) * 2016-04-15 2018-10-25 Felicitex Therapeutics, Inc. Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
AU2019262589B2 (en) 2018-05-04 2022-07-07 Amgen Inc. KRAS G12C inhibitors and methods of using the same
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
SG11202112855WA (en) 2019-05-21 2021-12-30 Amgen Inc Solid state forms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005002571A1 (en) * 2003-07-03 2005-01-13 Cambridge University Technical Services Ltd Use of aurora kinase inhibitors for reducing the resistance of cancer cells
US7560551B2 (en) * 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
JP5280862B2 (ja) 2006-01-23 2013-09-04 アムジエン・インコーポレーテツド オーロラキナーゼ調節剤および使用方法
CN101405282B (zh) * 2006-01-23 2015-03-25 安姆根有限公司 极光激酶调节剂和使用方法
GB0609619D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Combination
GB0609621D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal

Also Published As

Publication number Publication date
SI2475368T1 (sl) 2015-03-31
EP2818170A1 (en) 2014-12-31
JP2013504582A (ja) 2013-02-07
NZ598758A (en) 2013-12-20
UA107675C2 (en) 2015-02-10
CA2773838C (en) 2016-05-31
ES2528485T3 (es) 2015-02-10
EP2475368B1 (en) 2014-12-17
HK1205457A1 (en) 2015-12-18
HUE024568T2 (hu) 2016-02-29
US20120028917A1 (en) 2012-02-02
BR112012008325A2 (pt) 2017-08-29
ZA201202472B (en) 2012-12-27
MX2012003041A (es) 2012-06-27
HK1173655A1 (en) 2013-05-24
CN102869361A (zh) 2013-01-09
EP2475368A1 (en) 2012-07-18
JP5851403B2 (ja) 2016-02-03
TW201121956A (en) 2011-07-01
PE20120895A1 (es) 2012-08-19
PL2475368T3 (pl) 2015-05-29
TN2012000110A1 (en) 2013-09-19
AU2010292225B2 (en) 2012-12-13
SG179102A1 (en) 2012-04-27
EA201270383A1 (ru) 2013-04-30
EP2818170B1 (en) 2018-12-05
ME02048B (me) 2015-05-20
SMT201500028B (it) 2015-03-05
AU2010292225A1 (en) 2012-04-12
IL218569A0 (en) 2012-05-31
HRP20150104T1 (en) 2015-03-13
DK2475368T3 (en) 2015-03-09
KR20120082896A (ko) 2012-07-24
PT2475368E (pt) 2015-02-10
RS53807B1 (en) 2015-06-30
CA2773838A1 (en) 2011-03-17
AU2010292225C1 (en) 2013-06-27
EA020526B1 (ru) 2014-11-28
CR20120171A (es) 2012-08-09
WO2011031842A1 (en) 2011-03-17
MA33658B1 (fr) 2012-10-01

Similar Documents

Publication Publication Date Title
CL2012000640A1 (es) Uso del compuesto n-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamina o su sal para el tratamiento de cancer refractario a tratamiento con un agente anti-cancer.
NI200900184A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer.
CR11757A (es) Compuestos de triazina como inhibidores mtor y quinasa pi3
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
EA201170832A1 (ru) Пуриновые соединения
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
MX2016010572A (es) Compuestos heterociclicos aromaticos como compuestos antiinflamatorios.
EA201171367A1 (ru) Винилиндазолильные соединения
DOP2012000006A (es) Agonista de gpr119
MX344335B (es) Derivados de benzonitrilo como inhibidores de cinasa.
BRPI0814772A2 (pt) Indazóis substituídos por 5-piridinona
BR112013010136A2 (pt) vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma
SMT201500086B (it) Uso del nifuratel per il trattamento di infezioni causate dalla specie atopobium
EA201270728A1 (ru) Пуриновые соединения
NI201100184A (es) Antagonistas de ccr3 de arilsulfonamida 2, 5 - disustituida
CL2011000168A1 (es) Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer.
CY1119483T1 (el) Θεραπευτικος παραγων για τις αγχωδεις διαταραχες
CL2011002625A1 (es) Compuestos derivados de 3-(piridin-3-il-etinil)-piridina; preparaciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes.
UA112746C2 (uk) Протиракові стероїдні лактони, ненасичені в положенні 7(8)
EA201500737A1 (ru) Пиразолилкарбоксамиды ii в качестве ингибиторов crac каналов
EA201500736A1 (ru) Пиразолилкарбоксамиды i в качестве ингибиторов crac каналов
ES2530755T3 (es) Terapia de combinación para el tratamiento del cáncer
EA201291384A1 (ru) Терапевтические агенты 976
EA201270547A1 (ru) Фармацевтическая композиция
CL2012000753A1 (es) Compuestos derivados de 2-(difluorometil)-4-(1h-indazol-5-il)-1,4-dihidropiridina-3,5-dicarbonitrilo y sus sales; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de un trastorno proliferativo celular, tal como cancer.